Interin CEO, Jerry Kanellos [email protected]
Investor relations, Peter Taylor [email protected]
Have had success with Peter previously, however Jerry is yet to personally respond to any of my emails over the years. Closest indication regarding a response was to this email I sent mid September.
"Dear Jerry,
I did contact Peter Taylor, investor relations, however he was unable to answer my question.
My question relates to the fact that Immuron have previously stated that top-line results for the phase 2 Pediatric NAFLD study would be released 4Q 2018 however the NIH via their website clinicaltrials.gov are indicating that the trial will not be completed until May 2019. Obviously such a setback would have negative effects upon the share price particularly the options IMCOB expiring Nov 19.
Based upon present indications, when will the Pediatric NAFLD Phase 2 study be completed? and when will the top-line results be released?"
I did not receive a call or an e-mail, however a few weeks latter the corporate presentation:
https://www.immuron.com.au/assets/files/Immuron Corporate Presentation - HCW Conference 2018 V2.pdf
was released on IMC website with the updated dates regarding top-line results.
It is time for all to apply some pressure.
Interin CEO, Jerry Kanellos [email protected] Investor...
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.79M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 51067 | 1 |
View Market Depth
| Last trade - 16.12pm 03/10/2024 (20 minute delay) ? |
| IMC (ASX) Chart |
Day chart unavailable